OxyContin

OxyContin
IUPAC name	(5R,9R,13S,14S)-4,5α-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
Tradename	OxyContin, others
Drugs.com	Monograph
MedlinePlus	a682132
Routes of administration	By mouth
CAS number	76-42-6
ATC prefix	N02
ATC suffix	AA05
PubChem	5284603
DrugBank	DB00497
ChemSpiderID	4447649
UNII	CD35PMG570
KEGG	D08141
ChEBI	7852
ChEMBL	659

OxyContin. It is a brand name for a time-release formulation of the semi-synthetic opioid oxycodone, developed and marketed by the pharmaceutical company Purdue Pharma. First approved by the Food and Drug Administration in 1995, it was aggressively promoted for the management of moderate to severe chronic pain. Its introduction and subsequent widespread prescribing practices are widely considered a catalyst for the opioid epidemic in the United States, leading to extensive litigation, regulatory scrutiny, and profound societal impact.

History

The development of OxyContin was driven by Purdue Pharma, a privately held company owned by the Sackler family, seeking to expand the market for oxycodone. Following FDA approval, the company launched an unprecedented marketing campaign directed at physicians, which minimized risks of addiction and overstated benefits for non-cancer pain. Key figures in this effort included former president Richard Sackler and marketing executive Michael Friedman. The campaign successfully transformed prescribing patterns, significantly increasing sales. The release of the drug coincided with a broader shift in pain management philosophy, advocated by organizations like the American Pain Society, which emphasized pain as a vital sign.

Medical uses

It is indicated for the management of severe pain requiring continuous, around-the-clock opioid treatment for an extended period, where alternative treatment options are inadequate. Approved uses typically include pain associated with advanced cancer or severe osteoarthritis. Its use is generally reserved for patients who are already opioid-tolerant. Clinical guidelines from bodies like the Centers for Disease Control and Prevention now strongly recommend against its initiation for most types of chronic pain due to high risks. It is contraindicated in conditions like acute asthma or gastrointestinal obstruction.

Pharmacology

The active pharmaceutical ingredient, oxycodone, is a potent μ-opioid receptor agonist, producing its analgesic effects primarily within the central nervous system. It is metabolized in the liver via the cytochrome P450 system, predominantly by the CYP3A4 and CYP2D6 enzymes, into metabolites including noroxycodone and oxymorphone. The original formulation utilized a patented controlled-release delivery system intended to provide steady drug levels over 12 hours. However, the tablet could be easily crushed or dissolved, defeating the time-release mechanism and delivering a potentially lethal dose of opioid all at once.

Controversies and legal issues

Purdue Pharma faced massive litigation for its role in fueling the opioid crisis. Landmark cases include the 2007 federal prosecution in the Western District of Virginia, where the company and three executives pleaded guilty to misbranding charges. A pivotal lawsuit by the Commonwealth of Massachusetts alleged the Sacklers directed deceptive practices. In 2019, Purdue Pharma filed for Chapter 11 bankruptcy protection. A controversial settlement plan, involving contributions from the Sackler family and dissolution of Purdue, was ultimately upheld by the Supreme Court of the United States in 2024. Investigations by the United States Congress and documentaries like *The Crime of the Century* detailed the corporate misconduct.

Society and culture

The drug became a central symbol of the opioid epidemic, profoundly affecting communities across Appalachia and the Rust Belt. Its abuse and diversion were depicted in cultural works such as the television series *Dopesick* and the book *Dreamland* by Sam Quinones. High-profile deaths, including that of musician Prince, were linked to fentanyl but underscored the trajectory from prescription opioids. The crisis spurred activism by groups like PAIN (Prescription Addiction Intervention Now) and led to widespread public scrutiny of the pharmaceutical industry's influence on American medicine.

Formulations and regulation

The original formulation was subject to widespread abuse. In response, the FDA approved a reformulated, abuse-deterrent version in 2010, designed to resist crushing and form a gel when dissolved. Subsequent regulations from the Drug Enforcement Administration placed stricter production quotas on oxycodone. Prescribing is now heavily monitored through Prescription Drug Monitoring Programs in all states. Other branded and generic extended-release oxycodone products, such as Xtampza ER, also incorporate abuse-deterrent technologies under FDA guidance.

Category:Opioids Category:Controlled substances Category:Opioid epidemic in the United States